Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices — United States, June 2021Julia W. Gargano, Sara E. Oliver, Heather M. Scobie et al.|MMWR Morbidity and Mortality Weekly Report|2021Cited by 602
Prevention and Control of Seasonal Influenza with VaccinesLisa A. Grohskopf, Joseph Bresee, Leslie Z. Sokolow et al.|MMWR Recommendations and Reports|2016Cited by 601
Prevention and Control of Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices, United States, 2015–16 Influenza SeasonLisa A. Grohskopf, Ruth A. Karron, Leslie Z. Sokolow et al.|MMWR Morbidity and Mortality Weekly Report|2015Cited by 277
Prevention and Control of Seasonal Influenza With Vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP)—United States, 2014–15 Influenza SeasonLisa A. Grohskopf, Emmanuel B. Walter, Sonja J. Olsen et al.|American Journal of Transplantation|2014Cited by 265
Outcomes at least 90 days since onset of myocarditis after mRNA COVID-19 vaccination in adolescents and young adults in the USA: a follow-up surveillance studyIan Kracalik, Jacek M. Mazurek, Matthew E. Oster et al.|The Lancet Child & Adolescent Health|2022Cited by 78